Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Rhea-AI Summary

Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2025 RBC Capital Markets Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. Investors and interested parties can access the live webcast through the company's website at www.designtx.com, where it will remain archived for at least 30 days after the presentation.

News Market Reaction – DSGN

-1.38%

-1.38% Session move

In the trading session that priced this news, DSGN declined 1.38%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.

A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC^® gene targeted chimera small molecules. The company’s GeneTAC^® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC^® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

FAQ

When is Design Therapeutics (DSGN) presenting at the 2025 RBC Capital Markets Healthcare Conference?

Design Therapeutics will present on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.

Where can I watch Design Therapeutics' (DSGN) presentation at the RBC Healthcare Conference?

The presentation can be accessed via live webcast through Design Therapeutics' website at www.designtx.com in the investors section.

How long will Design Therapeutics' (DSGN) RBC Conference presentation be available to view?

The webcast will be archived for at least 30 days following the presentation on the company's website.

What type of company is Design Therapeutics (DSGN)?

Design Therapeutics is a clinical-stage biotechnology company that develops treatments for serious degenerative genetic diseases.